CAJ | 학술논문

术前新辅助治疗对食管癌远期生存率的影响仍有争议,但研究显示只有新辅助治疗后取得病理学显著缓解的患者才能从新辅助治疗中获益.因此,建立病理反应预测指标有助于筛选出食管癌新辅助治疗获益人群,实现个体化综合治疗模式.
술전신보조치료대식관암원기생존솔적영향잉유쟁의,단연구현시지유신보조치료후취득병이학현저완해적환자재능종신보조치료중획익.인차,건립병리반응예측지표유조우사선출식관암신보조치료획익인군,실현개체화종합치료모식.
Although the effect of trimodality(neoadjuvant treatment) on survival rate is contradic tionary,who achieves pathological response can derive a survival benefit Predictive markers of pathological response would be valuable in individualising patient treatment,it would enable discrimination of those patients likely to respond to combination therapy from those likely to be non-responsive and may progress during therapy.Here we review roles of histopathology,functional imaging and molecular markers in predicting response to neoadjuvant treatment.